Allergan receives authorisation for uveitis treatment

Allergan receives authorisation for uveitis treatment

Allergan has announced that the European Medicines Agency (EMA) has extended the Marketing Authorisation for OZURDEX in the 27 member states of the EU to include the treatment of inflammation of the posterior segment of the eye presenting as non-infectious uveitis. OZURDEX is already available in many countries in Europe as the first treatment licensed for macular oedema in patients with retinal vein occlusion (RVO).

Latest Articles
Simulators Benefit Surgeons and Patients

Helping young surgeons build confidence and expertise.

Read more...

How Many Surgeries Equal Surgical Proficiency?

Internet, labs, simulators, and assisting surgery all contribute.

Read more...

Improving Clinical Management for nAMD and DME

Global survey data identify barriers and opportunities.

Read more...

Are Postoperative Topical Antibiotic Drops Still Needed?

Cataract surgeons debate the benefits of intracameral cefuroxime prophylaxis.

Read more...

Emerging Technology for Detecting Subclinical Keratoconus

Brillouin microscopy shows promise in clinical studies.

Read more...

Knowing Iris Repair: Modified Trifold Technique

Part eight of our series covers the modified trifold technique for large iris defects.

Read more...

It’s All About Biomechanics!

Increasing the pool of patients eligible for refractive surgery.

Read more...

Uncovering More Safe and Quick Options

Different strategies, such as PresbyLASIK, can offer presbyopes good outcomes.

Read more...

Topography-Guided PRK for Keratoconus

Improving visual acuity in patients with keratoconus.

Read more...

Defining AMD Treatment Protocol

Treatments trending to fewer injections for better results.

Read more...